about
Expression profiling predicts outcome in breast cancerLong non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasisInternational network of cancer genome projects.Genes that mediate breast cancer metastasis to the brainDetermination of stromal signatures in breast carcinoma.Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancersHER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.Gene expression profiling predicts clinical outcome of breast cancerA gene-expression signature as a predictor of survival in breast cancerHER2 testing in gastric cancer: a practical approachClinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patientsThe landscape of cancer genes and mutational processes in breast cancerBRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.Gene expression programs of human smooth muscle cells: tissue-specific differentiation and prognostic significance in breast cancers.SIRAC: Supervised Identification of Regions of Aberration in aCGH datasets.Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stabilityIdentification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.Landscape of somatic mutations in 560 breast cancer whole-genome sequences.MicroRNA sequence and expression analysis in breast tumors by deep sequencing.Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.Integration of clinical and gene expression data has a synergetic effect on predicting breast cancer outcomeGenetic regulators of large-scale transcriptional signatures in cancer.A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters.Emerging technologies for assessing HER2 amplification.The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.Current perspectives on HER2 testing: a review of national testing guidelines.Retrospective analysis of metastatic behaviour of breast cancer subtypesImpact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trialsPredicting a local recurrence after breast-conserving therapy by gene expression profiling.Classification of ductal carcinoma in situ by gene expression profiling.The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humansDNA ploidy of primary breast cancer and local recurrence after breast-conserving therapy.Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancerExpression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapyFunctional characterization of the 19q12 amplicon in grade III breast cancers
P50
Q21195186-EED1A720-1D87-48DD-9242-02CFB6EE543FQ24607308-D63B797C-4F5E-4B7C-A2FA-0377C9CE7977Q24611474-1A05BA6E-2969-446C-9CA3-A2267EAC8F6CQ24611474-AC33F464-CA77-40B9-830A-9F234BE6638AQ24644008-1D838889-5084-4F3F-92CD-271C8036739CQ24798099-4BEA96B5-B735-423A-ABCE-5F2FAE2ADEC6Q25255387-18D81A17-1E5D-41F7-B11D-14791AEB506BQ27006811-B0EFC819-86D4-471D-BC08-7B72E840DAD3Q27851414-3FCCD18E-2686-49E5-AB0F-63A3B3ADF4E5Q27860732-3F10A2FC-3EE1-4B34-BFE4-36F1CF89E62EQ27860945-6E31E342-13BE-4486-9E18-CB44C1F623C4Q28256814-C3CF2FCF-C0FC-44C5-8B5F-DA84C7CD8D3CQ28365020-98ECA5F8-C835-4A8D-92DC-E3824D1AB803Q29614637-65607DFC-DA6B-4190-BD8B-F91B29210A02Q30497664-FF08729E-9928-4ED9-A522-218261234F16Q33301016-8217FB0C-781A-41E4-B91A-E707F83FAF4FQ33304400-0114C9BC-4454-4A8E-AC98-061D434E42EDQ33358309-5E4E26E1-AC69-43DC-A381-F77AA2FC5FB4Q33741864-ADE4E4D0-78A1-422E-A612-893F783721D4Q33831109-B1749018-C5F1-4A19-8AC0-D6B8825A29B0Q34046731-0E768AFD-F85A-492E-AFC5-3ACE60CACDFFQ34185623-21B1FA1A-7E67-400B-A88C-EE40BE5C2E54Q34220452-FF08AE26-C5A0-4B89-987D-4D3F9BA1A280Q34325583-EF10A74B-B66D-4A2F-A973-35C36B5B1830Q34341956-75AACAEF-B4F1-4188-AE03-04950A9E2062Q34537800-455995FE-F13F-4391-9E1A-07E183E67123Q34557719-624C8F94-316A-455A-ABF2-4D9379A3204FQ34629890-E2E7E4AE-D8B0-4B7D-A95D-20F8EFAD7E7DQ34659152-8DD73594-79AD-4965-9BC8-D9F8CB861D37Q35007777-12748EE3-4696-4717-977A-87BE3338BE8DQ35064705-7A0C7571-D87C-4B17-A617-5618C6FE7D7EQ35068197-0E6BA92B-7C67-430D-88E4-FE70F8C1CBA9Q35252752-1C2A8E3D-C398-4EDF-BCBA-3004839BA69AQ35558130-F1707C78-99D9-4898-BB5E-5687BB497349Q35605850-EFDFDCA2-8B75-4079-ABAD-B58A160A79C4Q35605885-74BAF554-93FD-433B-9EDB-3628599196C5Q35758261-5022AD29-09D1-461D-92E2-847E0EA72D72Q35992783-A74DA34E-E302-4B8C-A9AF-4EAF917552DFQ36092726-75EB5DA9-9684-4652-BA4A-15817421FA86Q36135680-24F389DE-D695-48C0-A9C6-631280E5301E
P50
description
onderzoeker
@nl
name
Marc van de Vijver
@ast
Marc van de Vijver
@en
Marc van de Vijver
@sl
type
label
Marc van de Vijver
@ast
Marc van de Vijver
@en
Marc van de Vijver
@sl
prefLabel
Marc van de Vijver
@ast
Marc van de Vijver
@en
Marc van de Vijver
@sl